Abstract: The invention relates to poly(phosphoesters), compositions comprising the poly(phosphoesters), and methods of use.

Abstract: A method, and mediating agents are provided for mediating the physiological effects of hormones, neurotransmitters, calcium-channel antagonists, chemotactic peptides or chemotactic proteins. The mediating agents provided herein are bioactive conformations of peptide hormones, neurotransmitters, calcium-channel antagonist drugs or chemotatic peptides, or analogues, agonists or antagonists thereof, or synthetic analogue substances, having Ca.sup.2+ and/or Mg.sup.2+ ions optimally and optimally-conformationally bound to the respective compound. The Ca.sup.2+ antagonist/agonist may bind Mg.sup.2+ and thus may also block calcium-channel. In the one method, the concentration of intracellular Ca.sup.2+ is raised by means of such mediating agents. A second method is also provided for delivering Ca.sup.2+ and/or Mg.sup.2+ to a membrane-bound receptor by transporting Ca.sup.2+ and/or Mg.sup.2+ through a cell membrane using the above-described mediating agents.

Abstract: Benzyl esters of the formula I ##STR1## where R.sup.1 is methyl, ethyl, halogen, methoxy or ethoxy, R.sup.2 is alkyl, alkenyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl, C.sub.1 -C.sub.5 -alkyl-substituted cycloalkyl, C.sub.1 -C.sub.5 -substituted cycloalkenyl, C.sub.1 -C.sub.5 -alkyl-substituted bicycloalkyl or C.sub.1 -C.sub.5 -alkyl-substituted bicycloalkenyl, R.sup.3 is hydrogen, cyano, C.sub.2 -C.sub.4 -alkynyl, C.sub.2 -C.sub.4 -alkenyl or C.sub.1 -C.sub.4 -alkyl, A is the carboxylate radical of an acid component typical for pyrethroids and X is hydrogen or halogen, with the proviso that R.sup.2 is not CH.sub.2 --CH.dbd.CH--B when B is hydrogen, alkyl or alkenyl and at the same time R.sup.1 is methyl or halogen, and furthermore with the proviso that R.sup.2 is not methyl when R.sup.1 is methyl, their manufacture, their use for combating pests, and precursors for manufacturing the benzyl esters.

Abstract: The invention provides a superoxide dismutase derivative of the general formula[SOD][Z].sub.nwherein [SOD] represents a superoxide dismutase having 1 to 22 or 24 groups each derived from an amino group by removal of one hydrogen atom in lieu of amino groups; [Z] represents a monovalent copolymer group, constituting units of which are a group of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each represents a hydrogen atom or a residue derived by removal of a hydroxyl group from an alkanol of 1 to 8 carbon atoms, an ethylene glycol monoalkyl ether containing an alkyl moiety of 1 to 4 carbon atoms or a glycerin dialkyl ether containing alkyl moieties of 1 to 4 carbon atoms, provided that either R.sup.1 or R.sup.2 and either R.sup.3 or R.sup.4 each represents a hydrogen atom, and a residue derived from the group of the above-mentioned formula by removal of OR.sup.1, OR.sup.2, OR.sup.3 or OR.sup.4 group from one of its COOR.sup.1, COOR.sup.2, COOR.sup.3 and COOR.sup.

Abstract: The present invention provides methods for treating or preventing various dermatological conditions in humans, such as dry, cracked or damaged skin resulting from exposure to sunlight (ultraviolet radiation) and wind, aging effects, general skin dryness, e.g., deficient moisture content, and mild acne. These methods comprise applying an effective amount of a composition to the affected target area, the composition comprising a retinyl palmitate-polypeptide complex of apparent molecular weight of from about 5,000 to about 7,000 daltons, and an isoprenoid compound, e.g., a carotenoid such as beta-carotene.

Abstract: Compounds of the formula: ##STR1## which are potent inhibitors of human renin and are useful for treating various forms of renin-associated hypertension, hyperaldosteronism and congestive heart failure; compositions containing these renin-inhibitory compounds, optionally with other antihypertensive agents; and methods of treating hypertension, hyperaldosteronism or congestive heart failure or of establishing renin as a causative factor in these conditions which employ these novel compounds.

Abstract: The invention relates to a tetrapeptide corresponding to the general formulaSer-Asp-Lys-Pro--OHand its substitution derivatives by one or several groups, identical or different, currently used in the chemistry of peptides for biological use, as well as their pharmaceutically acceptable salts, in particular the tetrapeptideSer-(N-Ac)-Asp-Lys-Pro--OHwhich can be extracted, for example, from fetal calf marrow or obtained by peptide synthesis.The peptide of the invention is particularly useful in the protection of bone marrow in the course of anti-cancer treatments by chemotherapy.

Abstract: Light activated acyl-enzymes of the formula: ##STR1## are disclosed. In the compounds of Formula (III), ENZ is an enzyme, X is O or S, Y is --NR.sub.3 R.sub.4, --OR.sub.5, or --SR.sub.5, and Z is a nucleophile. m is 0 to 3 and n is 1 or 2. Y is substituted on the ring at either or both of the 4 and 6 position.R.sub.1 and R.sub.2 are each independently H, C1 to C4 alkyl, C3 to C4 unconjugated alkenyl, or C3 to C4 unconjugated alkynyl.R.sub.3 and R.sub.4 are each independently H, C1 to C4 alkyl, C3 to C4 unconjugated alkenyl, or C3 to C4 unconjugated alkynyl, except that R.sub.3 and R.sub.4 are not simultaneously both H. R.sub.5 is C1 to C4 alkyl, C3 to C4 unconjugated alkenyl, or C3 to C4 unconjugated alkynyl.Methods of using the acyl-enzymes and intermediates for making the acyl-enzymes are disclosed.

Abstract: The present invention relates to compositions useful as thickening agents for aqueous systems. More particularly, it relates to compositions comprising smectite clays and cationic polymers.

Abstract: A series of carboxyl-containing N-alkyldipeptides have been found to posess antiviral potency--specifically against herpes simplex virus--by selectively inhibiting the viral ribonucleotide reductase enzyme.

Abstract: A method is provided for inhibiting growth of cancer cells comprising contacting said cells with an effective growth-inhibiting amount of a compound of the formula (II): ##STR1## or a physiologically acceptable salt thereof, wherein A.sup.1 and A.sup.2 are individually L-amino acid residues selected from the group consisting of Ala, Pro, Gly, Glu, Leu, Lys, Phe, Ser, Val, Ile, Arg, Tyr, Thr, Asp, Asn and Gly; R.sup.1 is C.sub.1 -C.sub.6 (alkyl) which is unsubstituted or is substituted with an aromatic substituent or one or more in-chain bivalent groups selected from the group consisting of --O--, --CO--, --S--, --NH--, --CONH--, CH.dbd.CH--, and --SO.sub.2 --; Y.sup.1 and Y.sup.2 are each H, or taken together from a moiety derived from a dihydroxy compound, and R.sup.1 is H or an N-terminal protecting group.

Abstract: The invention is new renin inhibitor dipeptide and tripeptide derivatives of the formula: ##STR1##

Abstract: Homogeneous, stable liquid compositions are provided comprising a carrier, e.g., a plasticizer, a solvent selected from C.sub.5 to C.sub.9 aliphatic alcohols and diols, e.g., isodecyl alcohol, 2-ethyl hexanol, 2-ethyl-1, 3-hexanediol or mixtures thereof, and a microbiocidal compound soluble in said solvent wherein the microbiocidal compound is present in amounts greater than 2.5 percent by weight of the combined weight of carrier, solvent and microbiocidal compound.

Abstract: A new lipase and a new protease, which can be produced by a new Pseudomonas strain, and methods of producing such lipase and protease using said strain, protease, or producing enzymatic additives for detergents whose main active component is the lipase of the invention. Further disclosed are detergent washing compositions containing the lipase and/or the protease or the enzymatic additives, and a washing process using said compositions.

Abstract: New bicyclic compounds, inclusive of salts thereof, of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represents hydrogen, hydroxyl or lower alkoxy, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is hydrogen, lower alkyl, amino-lower-alkyl or acylamino-lower-alkyl, R.sup.5 is hydrogen, lower alkyl or aralkyl which may be substituted, R.sup.6 is hydroxyl, lower alkoxy, amino or lower alkylamino, and m and n each means 1 or 2, have inhibitory activities of angiotensin converting enzyme and bradykinin decomposing enzyme, and are useful as antihypertensive agents.

Abstract: A synthetic peptide of the human malaria Plasmodium vivax, containing at st one repeat of a synthetic peptide having the amino acid sequence Ala-Gly-Asp-Arg (AGDR) which is a protective epitope found on the circumsporozoite (CS) protein of the sporozoites of the human maleria Plasmodium vivax. When a monoclonal antibody specific for this four amino acid sequence binds to the CS protein of the P. vivax sporozoite in vivo, infection is prevented. Also described are pharmaceutical formulations of these peptides.

Abstract: Neutral lipids are provided characterized by binding to phorboid and ingenoid receptors. These lipids are found in a wide variety of cellular sources as well as milk and may be isolated by specific extraction and chromatographic procedures. Depending upon the source, the glycerides may be mono- or di-glycerides, wherein the total number of carbon atoms of the fatty acis is in the range of 18 to 26, so that the monoglyceride has a fatty acid of at least 18 carbon atoms, while the di-glyceride has a fatty acid of at least 14 carbon atoms. The long chain fatty acids have at least one site of olefinic unsaturation.

Abstract: Disclosed is a process by which a gas containing nitric oxide is contacted with an anaerobic microbial culture of denitrifying bacteria to effect the chemical reduction of the nitric oxide to elemental nitrogen. The process is particularly suited to the removal of nitric oxide from flue gas streams and gas streams from nitric acid plants. Thiobacillus dentrificians as well as other bacteria are disclosed for use in the process.

Abstract: Compositions of zwitterionic drugs for transdermal administration and methods of administering zwitterions transdermally are disclosed. The compositions comprise a zwitterionic drug in a salt form and a solvent therefor.

Abstract: Disclosed are DC115A compounds represented by the following general formula: ##STR1## wherein R represents ethyl, propyl or 1-propenyl, and which have antibacterial and anti-tumor activity. DC115A compounds are produced by culturing a microorganism belonging to the genus Streptomyces.